IL248220A0 - Anti- nme antibody - Google Patents

Anti- nme antibody

Info

Publication number
IL248220A0
IL248220A0 IL248220A IL24822016A IL248220A0 IL 248220 A0 IL248220 A0 IL 248220A0 IL 248220 A IL248220 A IL 248220A IL 24822016 A IL24822016 A IL 24822016A IL 248220 A0 IL248220 A0 IL 248220A0
Authority
IL
Israel
Prior art keywords
nme
antibody
nme antibody
Prior art date
Application number
IL248220A
Other languages
English (en)
Hebrew (he)
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/050773 external-priority patent/WO2015023694A2/en
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Publication of IL248220A0 publication Critical patent/IL248220A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
IL248220A 2014-04-07 2016-10-06 Anti- nme antibody IL248220A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461976390P 2014-04-07 2014-04-07
PCT/US2014/050773 WO2015023694A2 (en) 2013-08-12 2014-08-12 Method for enhancing tumor growth
USPCT/US2014/061821 2014-10-22
US201562114526P 2015-02-10 2015-02-10
US201562127746P 2015-03-03 2015-03-03
PCT/US2015/024764 WO2015157322A2 (en) 2014-04-07 2015-04-07 Anti-nme antibody

Publications (1)

Publication Number Publication Date
IL248220A0 true IL248220A0 (en) 2016-11-30

Family

ID=54288530

Family Applications (2)

Application Number Title Priority Date Filing Date
IL248220A IL248220A0 (en) 2014-04-07 2016-10-06 Anti- nme antibody
IL291164A IL291164A (en) 2014-04-07 2022-03-07 Anti-nme antibody

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL291164A IL291164A (en) 2014-04-07 2022-03-07 Anti-nme antibody

Country Status (11)

Country Link
US (4) US20170204196A1 (cg-RX-API-DMAC7.html)
EP (2) EP4050103A1 (cg-RX-API-DMAC7.html)
JP (5) JP6401292B2 (cg-RX-API-DMAC7.html)
KR (2) KR102294483B1 (cg-RX-API-DMAC7.html)
CN (1) CN106414726A (cg-RX-API-DMAC7.html)
AU (1) AU2015243948B2 (cg-RX-API-DMAC7.html)
CA (1) CA2945162A1 (cg-RX-API-DMAC7.html)
IL (2) IL248220A0 (cg-RX-API-DMAC7.html)
SG (2) SG11201608389RA (cg-RX-API-DMAC7.html)
TW (1) TWI746420B (cg-RX-API-DMAC7.html)
WO (1) WO2015157322A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201608389RA (en) 2014-04-07 2016-11-29 Minerva Biotechnologies Corp Anti-nme antibody
WO2016130726A1 (en) 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
US20190290692A1 (en) * 2016-10-11 2019-09-26 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and use of cleavage enzyme
CA3058190A1 (en) 2017-03-29 2018-10-04 Minerva Biotechnologies Corporation Agents for differentiating stem cells and treating cancer
JP7695193B2 (ja) * 2019-02-04 2025-06-18 ミネルバ バイオテクノロジーズ コーポレーション 抗ｎｍｅ抗体および癌または癌転移の治療方法
JP2023530039A (ja) * 2020-06-08 2023-07-12 ミネルバ バイオテクノロジーズ コーポレーション 抗ｎｍｅ抗体および癌または癌転移の治療方法
EP4172215A4 (en) * 2020-06-26 2024-11-20 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHOD OF TREATING CANCER OR CANCER METASTASES
IL316221A (en) 2022-04-12 2024-12-01 Minerva Biotechnologies Corp Anti-MUC1* variant antibodies and their uses
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases
WO2025049494A1 (en) 2023-08-29 2025-03-06 Minerva Biotechnologies Corporation Bacterial nme7 orthologs and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5631271A (en) 1986-11-29 1997-05-20 Serfontein; Willem J. Methods and preparations for the treatment and prophylaxis of metabolic disturbances
US5874285A (en) * 1996-09-13 1999-02-23 Incyte Pharmaceuticals, Inc. Polynucleotide encoding a novel human nm23-like protein
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
WO2001022920A2 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
US20050163784A1 (en) 2002-06-17 2005-07-28 Valentijn Linda J. Novel cancer therapies
US7202346B2 (en) * 2002-07-03 2007-04-10 Immunogen Inc. Antibodies to non-shed Muc1 and Muc16, and uses thereof
AU2003299643A1 (en) * 2002-12-04 2004-06-23 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
ES2624863T3 (es) 2005-06-08 2017-07-17 Millennium Pharmaceuticals, Inc. Métodos para identificación, evaluación, y tratamiento de pacientes con terapia de cáncer
WO2007072221A2 (en) 2005-11-10 2007-06-28 Aurelium Biopharma Inc. Surface marker-directed cancer therapeutics
AU2008265928A1 (en) 2007-06-18 2008-12-24 Medimmune, Llc Synergistic treatment of cells that express EphA2 and ErbB2
DK2334703T3 (en) 2008-09-17 2015-10-05 Innate Pharma Configurations and methods for detection of tlr3
WO2010042562A2 (en) 2008-10-06 2010-04-15 Minerva Biotechnologies Corporation Muc1* antibodies
WO2010042760A2 (en) 2008-10-08 2010-04-15 The Administrators Of The Tulane Educational Fund Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
KR20170075023A (ko) * 2009-06-11 2017-06-30 미네르바 바이오테크놀로지 코포레이션 줄기 세포 및 전구 세포를 배양하는 방법
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN103998598A (zh) * 2011-10-17 2014-08-20 米纳瓦生物技术公司 用于干细胞增殖和诱导的培养基
BR112014020697B1 (pt) 2012-02-24 2024-01-09 Alteogen Inc Anticorpo modificado compreendendo um motivo contendo cisteína na terminação do anticorpo, conjugado anticorpo-droga modificado compreendendo uma droga ligada ao anticorpo modificado e método de produção do mesmo
EP2834260A4 (en) * 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
SG11201606118SA (en) * 2012-07-24 2016-08-30 Minerva Biotechnologies Corp Nme variant species expression and suppression
JP6664219B2 (ja) * 2012-08-14 2020-03-13 ミネルバ バイオテクノロジーズ コーポレーション 幹細胞増強治療法
US9770011B2 (en) 2012-09-29 2017-09-26 The Trustees Of The University Of Pennsylvania Veterinary composition and methods for non-surgical neutering and castration
IL240695B2 (en) * 2013-02-20 2024-03-01 Minerva Biotechnologies Corp Nme inhibitors and methods of using nme inhibitors
US20160326263A1 (en) 2013-02-20 2016-11-10 Minerva Biotechnologies Corporation NME Inhibitors and Methods of Using NME Inhibitors
SG11201608389RA (en) 2014-04-07 2016-11-29 Minerva Biotechnologies Corp Anti-nme antibody
WO2016130726A1 (en) 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
US11136399B2 (en) 2016-07-14 2021-10-05 Institute Of Biophysics, Chinese Academy Of Sciences Type I interferon receptor antibody and use thereof
EP3515949A4 (en) 2016-09-20 2020-10-28 Wuxi Biologics Ireland Limited. NEW ANTI-PCSK9 ANTIBODIES
US20190290692A1 (en) 2016-10-11 2019-09-26 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and use of cleavage enzyme
WO2019104306A1 (en) 2017-11-27 2019-05-31 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and direct use of cleavage enzyme
JP7695193B2 (ja) 2019-02-04 2025-06-18 ミネルバ バイオテクノロジーズ コーポレーション 抗ｎｍｅ抗体および癌または癌転移の治療方法
JP2023530039A (ja) 2020-06-08 2023-07-12 ミネルバ バイオテクノロジーズ コーポレーション 抗ｎｍｅ抗体および癌または癌転移の治療方法
EP4172215A4 (en) 2020-06-26 2024-11-20 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHOD OF TREATING CANCER OR CANCER METASTASES

Also Published As

Publication number Publication date
US20190031778A1 (en) 2019-01-31
KR102294483B1 (ko) 2021-08-27
AU2015243948B2 (en) 2020-10-15
JP2018203765A (ja) 2018-12-27
JP2017512825A (ja) 2017-05-25
TW201542595A (zh) 2015-11-16
EP4050103A1 (en) 2022-08-31
CA2945162A1 (en) 2015-10-15
JP2022095648A (ja) 2022-06-28
EP3129476A4 (en) 2017-11-08
US20220289865A1 (en) 2022-09-15
JP6401292B2 (ja) 2018-10-10
WO2015157322A3 (en) 2015-12-23
SG10201808867PA (en) 2018-11-29
US11702483B2 (en) 2023-07-18
WO2015157322A2 (en) 2015-10-15
US20190031779A1 (en) 2019-01-31
JP2020073562A (ja) 2020-05-14
EP3129476A2 (en) 2017-02-15
US20250011469A9 (en) 2025-01-09
TWI746420B (zh) 2021-11-21
IL291164A (en) 2022-05-01
EP3129476B1 (en) 2022-01-05
KR20160142372A (ko) 2016-12-12
AU2015243948A1 (en) 2016-10-27
JP2024084747A (ja) 2024-06-25
CN106414726A (zh) 2017-02-15
US12479928B2 (en) 2025-11-25
KR20210107166A (ko) 2021-08-31
SG11201608389RA (en) 2016-11-29
JP6646118B2 (ja) 2020-02-14
JP7042854B2 (ja) 2022-03-28
US20170204196A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
IL252004A0 (en) Ether-substituted antibody
IL250583A0 (en) Anti-tigit antibodies
SG11201703403TA (en) Anti-tim-3 antibodies
SG11201703346PA (en) Anti-tim-3 antibodies
IL252422B (en) Effector-deficient anti-cd32a antibodies
GB201411320D0 (en) Antibody construct
GB201410520D0 (en) Antibody
GB201515351D0 (en) Antibody
ZA201604640B (en) Novel anti-netrin-1 antibody
IL256519A (en) Anti-epha4 antibody
IL248220A0 (en) Anti- nme antibody
IL250374A0 (en) Antibodies against ceramide
GB201600871D0 (en) Antibody
HUE057499T2 (hu) Antitest
IL247988A0 (en) Antibodies against hpa–1a
SG11201700922YA (en) Anti-orai1 antibody
SI3628731T1 (sl) Novo protitelo proti presepsinu
GB201418776D0 (en) Antibody
GB201413745D0 (en) Antibody
GB201411319D0 (en) Antibody
GB201407535D0 (en) Antibody Drug - Conjugates
GB201419089D0 (en) Anti-TIM-3 antibodies
GB201419092D0 (en) Anti-TIM-3 antibodies
GB201417614D0 (en) Antibodies
GB201414270D0 (en) Antibodies